

**Oklahoma Health Care Authority  
Drug Utilization Review Board**

(DUR Board)

**Meeting – June 12, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. April 10, 2013 DUR Minutes – Vote
  - B. April 11, 2013 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Medication Coverage Activity for April & May 2013
  - B. Pharmacy Help Desk Activity for April & May 2013
  - C. Retrospective Drug Evaluation: Duplication of Narcotic Therapy

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Kynamro™ (Mipomersen) – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

6. **Action Item – Annual Review of Anticonvulsant Medications And 30-Day Notice to Prior Authorize Oxtellar XR™ (Oxcarbazepine ER) And Sabril® (Vigabatrin) – See Appendix D.**
  - B. Current Authorization Criteria
  - C. Utilization Review
  - D. Prior Authorization Review
  - E. Market News and Updates
  - F. Oxtellar XR™, Fycompa™, and Sabril® Product Summaries
  - G. COP Recommendations
  - H. Utilization Details
  - I. Oxtellar XR™, Fycompa™, and Sabril® Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Biologic Products for the Treatment of Rheumatoid Arthritis, Crohn’s Disease, Plaque Psoriasis, and Ankylosing Spondylitis – See Appendix E.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Testosterone Products – See Appendix F.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Multiple Sclerosis Medications And 30 Day Notice to Prior Authorize Aubagio® (Teriflunomide) and Tecfidera™ (Dimethyl Fumarate) – See Appendix G.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Tecfidera™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item - Annual Review of Leukotriene Modifiers: Singulair® (Montelukast) and Zyflo CR® (Zileuton) – See Appendix H.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Horizant® and Gralise™ (Gabapentin Extended-Release) – See Appendix I.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

**12. FDA and DEA Updates – See Appendix J.**

**13. Future Business**

- A. Safety Reviews
- B. Narcotic Prescriber Survey Results
- C. New Product Reviews
- D. Annual Reviews

**14. Adjournment**